Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by State Street Corp

State Street Corp lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,014,012 shares of the company's stock after purchasing an additional 110,162 shares during the period. State Street Corp owned about 4.36% of Pacira BioSciences worth $30,311,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PCRX. Centiva Capital LP acquired a new position in Pacira BioSciences during the third quarter worth approximately $398,000. PDT Partners LLC acquired a new position in shares of Pacira BioSciences in the 3rd quarter valued at $3,469,000. Verition Fund Management LLC purchased a new stake in Pacira BioSciences in the 3rd quarter valued at $493,000. FORA Capital LLC acquired a new stake in Pacira BioSciences during the 3rd quarter worth $431,000. Finally, BNP Paribas Financial Markets grew its position in Pacira BioSciences by 269.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock worth $5,955,000 after purchasing an additional 288,662 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Barclays reduced their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a research note on Friday, November 8th. Jefferies Financial Group lifted their target price on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. HC Wainwright restated a "buy" rating and set a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Royal Bank of Canada lifted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $23.50.

Pacira BioSciences Price Performance

Pacira BioSciences stock traded down $0.59 during mid-day trading on Friday, reaching $18.98. The company had a trading volume of 3,169,894 shares, compared to its average volume of 859,127. The company has a market capitalization of $876.36 million, a P/E ratio of -9.35 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The stock's 50-day simple moving average is $17.64 and its 200-day simple moving average is $18.58. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.95.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.